A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

In patients with locally advanced resectable oral squamous cell carcinoma (OSCC), the risk of recurrence and metastasis following treatment is high. Here, a phase I clinical trial reports safety and pathological response of neoadjuvant camrelizumab and apatinib in patients with locally advanced rese...

Full description

Bibliographic Details
Main Authors:	Wu-tong Ju, Rong-hui Xia, Dong-wang Zhu, Sheng-jin Dou, Guo-pei Zhu, Min-jun Dong, Li-zhen Wang, Qi Sun, Tong-chao Zhao, Zhi-hang Zhou, Si-yuan Liang, Ying-ying Huang, Yong Tang, Si-cheng Wu, Jing Xia, Shi-qing Chen, Yue-zong Bai, Jiang Li, Qi Zhu, Lai-ping Zhong
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-09-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-022-33080-8

Similar Items

Camrelizumab, chemotherapy and apatinib in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: a single-arm phase 2 trialResearch in context
by: Zixiang Wu, et al.
Published: (2024-05-01)

First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
by: Xiaofeng Chen, et al.
Published: (2024-03-01)

Phase Ib trial of camrelizumab combined with chemotherapy and apatinib for neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma
by: Zhen Wang, et al.
Published: (2022-06-01)

Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study
by: Haoran Xia, et al.
Published: (2024-06-01)

SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report
by: JiKe Hu, et al.
Published: (2024-07-01)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
by: Ke Wang, et al.
Published: (2022-04-01)

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study
by: Tian-Qi Zhang, et al.
Published: (2023-10-01)

Successful treatment of recurrent sarcomatous choledochal carcinoma with camrelizumab and apatinib
by: Shilei Li
Published: (2023-11-01)

The Safety and Efficacy of Camrelizumab and Its Combination With Apatinib in Various Solid Cancers
by: Kunlun Wang, et al.
Published: (2020-10-01)

RETRACTED: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Qing Yang, et al.
Published: (2023-03-01)

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
by: Jun Ni, et al.
Published: (2023-04-01)

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review
by: Xin-Liang Liu, et al.
Published: (2024-03-01)

Clinical Experience with Apatinib and Camrelizumab in Advance Clear Cell Sarcoma: A Retrospective Study
by: Wang J, et al.
Published: (2021-12-01)

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma
by: Lin Li, et al.
Published: (2024-06-01)

Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial
by: Jian-Xian Lin, et al.
Published: (2024-01-01)

412 CAMrelizumab and apatiniB combIned with chemoTherapy (mFOLFOX6) as neoadjuvant therapy for locally advanced rIght-sided colON cancer (AMBITION)
by: Wenbin Chen, et al.
Published: (2021-11-01)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
by: Xin Li, et al.
Published: (2022-09-01)

Camrelizumab plus apatinib for previously treated advanced adrenocortical carcinoma: a single-arm phase 2 trial
by: Yu-Chun Zhu, et al.
Published: (2024-11-01)

A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
by: Qingyuan Zhang, et al.
Published: (2022-10-01)

Camrelizumab in combination with neoadjuvant chemotherapy in resectable locally advanced esophageal squamous carcinoma cancer: Results from a retrospective study
by: Ning‐Ning Kang, et al.
Published: (2024-03-01)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
by: Jieqiong Liu, et al.
Published: (2022-05-01)

Efficacy of China-produced Camrelizumab with Apatinib for First-line Treatment in Middle and Advanced Stages of Primary Liver Cancer
by: Jinfa XU, Wencan SONG, Zhongxian ZHENG, Yu BAO, Gaoyan HUA, Qing CAI, Weiwei SHI, Xiufang ZHANG, Jianhua ZHANG, Zhou TONG, Guoan XIA, Fei LIU, Lintao LIU, Kesheng XIAO
Published: (2022-09-01)

Transcatheter arterial chemoembolization of apatinib and camrelizumab (SHR1210) against liver metastasis from hepatic neuroendocrine tumor: a case report
by: Ruobing Qi, et al.
Published: (2024-02-01)

Neoadjuvant therapy of sequential TACE, camrelizumab, and apatinib for single huge hepatocellular carcinoma (NEO-START): study protocol for a randomized controlled trial
by: Yun Hao, et al.
Published: (2024-07-01)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
by: Wenling Ye, et al.
Published: (2023-07-01)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
by: Di Zhu, et al.
Published: (2022-11-01)

Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
by: Qiang Liu, et al.
Published: (2020-05-01)

Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial
by: Li Yuan, et al.
Published: (2023-08-01)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
by: Yonghao Yang, et al.
Published: (2021-10-01)

Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination
by: Shuguang Ju, et al.
Published: (2022-03-01)

Camrelizumab and apatinib plus induction chemotherapy and concurrent chemoradiotherapy in stage N3 nasopharyngeal carcinoma: a phase 2 clinical trial
by: Hu Liang, et al.
Published: (2024-02-01)

Assessing the effectiveness of camrelizumab plus apatinib versus sorafenib for the treatment of primary liver cancer: a single-center retrospective study
by: Dongbo Chen, et al.
Published: (2023-08-01)

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study
by: Yanfei Liu, et al.
Published: (2023-04-01)

Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer
by: Liang Shi, et al.
Published: (2022-10-01)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
by: Zhichao Liao, et al.
Published: (2019-02-01)

Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial
by: Qinglian Tang, et al.
Published: (2024-09-01)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
by: Shuguang Ju, et al.
Published: (2022-01-01)

Retraction: A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
by: Frontiers Editorial Office
Published: (2024-02-01)

Neoadjuvant chemoradiotherapy with camrelizumab in patients with locally advanced esophageal squamous cell carcinoma
by: Fei Chen, et al.
Published: (2022-08-01)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
by: Jiaming Xu, et al.
Published: (2020-11-01)